Published in J Natl Cancer Inst on February 01, 2006
Volume, process of care, and operative mortality for cystectomy for bladder cancer. Urology (2007) 2.07
Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol (2013) 1.72
Centralisation of services for gynaecological cancer. Cochrane Database Syst Rev (2012) 1.67
Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy. J Clin Oncol (2016) 1.48
Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. Gynecol Oncol (2015) 1.43
Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol (2008) 1.37
Transcending the volume-outcome relationship in cancer care. J Natl Cancer Inst (2006) 1.33
Do racial/ethnic disparities exist in the utilization of high-volume surgeons for women with ovarian cancer? Gynecol Oncol (2008) 1.26
Multivariate analyses to assess the effects of surgeon and hospital volume on cancer survival rates: a nationwide population-based study in Taiwan. PLoS One (2012) 1.10
Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival. J Am Coll Surg (2015) 1.02
Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer (2008) 1.01
Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol (2011) 0.85
Will patients benefit from regionalization of gynecologic cancer care? PLoS One (2009) 0.82
Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care. Nat Rev Clin Oncol (2015) 0.81
The effect of specialized cancer treatment centers on treatment efficacy in Hodgkin's lymphoma. Dtsch Arztebl Int (2012) 0.78
Relative impact of surgeon and hospital volume on operative mortality and complications following pancreatic resection in Medicare patients. J Surg Res (2016) 0.78
Disparities in use of gynecologic oncologists for women with ovarian cancer in the United States. Health Serv Res (2012) 0.75
If the Mountain Does Not Come to Mohammad: The Significance of Guest Operations for Early Stage Ovarian Cancer. J Gynecol Surg (2014) 0.75
In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon. J Obstet Gynaecol India (2016) 0.75
Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer. Gynecol Oncol (2015) 0.75
Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study. Gynecol Oncol (2017) 0.75
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002) 6.51
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Assessing comorbidity using claims data: an overview. Med Care (2002) 4.94
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol (2007) 4.81
Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol (2003) 4.77
How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol (2002) 4.68
Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst (2008) 4.53
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Use of SEER-Medicare data for measuring cancer surgery. Med Care (2002) 4.27
How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 4.24
Studying radiation therapy using SEER-Medicare-linked data. Med Care (2002) 4.13
Stimulation of lignocellulosic biomass hydrolysis by proteins of glycoside hydrolase family 61: structure and function of a large, enigmatic family. Biochemistry (2010) 3.70
Insights into the oxidative degradation of cellulose by a copper metalloenzyme that exploits biomass components. Proc Natl Acad Sci U S A (2011) 3.59
Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care (2002) 3.57
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Structure of the agonist-bound neurotensin receptor. Nature (2012) 3.23
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Differences between primary care physicians' and oncologists' knowledge, attitudes and practices regarding the care of cancer survivors. J Gen Intern Med (2011) 3.11
Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care (2006) 3.08
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (2011) 3.05
Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol (2011) 3.05
Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev (2009) 3.04
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99
Patient time costs associated with cancer care. J Natl Cancer Inst (2007) 2.90
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev (2012) 2.82
Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol (2012) 2.77
Acetylation of H2AZ Lys 14 is associated with genome-wide gene activity in yeast. Genes Dev (2006) 2.73
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
Clinicopathological features of and risk factors for multiple primary melanomas. JAMA (2005) 2.62
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood (2011) 2.59
Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med (2010) 2.59
Developing a cancer-specific geriatric assessment: a feasibility study. Cancer (2005) 2.57
Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem (2004) 2.45
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol (2009) 2.45
Oxidoreductive cellulose depolymerization by the enzymes cellobiose dehydrogenase and glycoside hydrolase 61. Appl Environ Microbiol (2011) 2.43
Is the easier way ever the better way? J Clin Oncol (2011) 2.41
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med (2003) 2.33
Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol (2006) 2.32
Barriers to breast and colorectal cancer survivorship care: perceptions of primary care physicians and medical oncologists in the United States. J Clin Oncol (2013) 2.32
Tembusu virus in ducks, china. Emerg Infect Dis (2011) 2.30
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Identifying cancer relapse using SEER-Medicare data. Med Care (2002) 2.28
Histone h3 lysine 56 acetylation is linked to the core transcriptional network in human embryonic stem cells. Mol Cell (2009) 2.27
Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst (2008) 2.23
Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg (2013) 2.19
Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol (2011) 2.18
Patterns of care in elderly glioblastoma patients. Ann Neurol (2008) 2.17
End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst (2011) 2.14
Association between incident cancer and subsequent stroke. Ann Neurol (2015) 2.13
Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst (2005) 2.08
Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain (2009) 2.05
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A (2005) 2.03
Data sources for measuring colorectal endoscopy use among Medicare enrollees. Cancer Epidemiol Biomarkers Prev (2007) 2.02
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer (2009) 2.01
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol (2008) 2.00
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol (2006) 1.98
When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst (2010) 1.95
Estimating patient time costs associated with colorectal cancer care. Med Care (2005) 1.94
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol (2012) 1.93
Estimation of labeling efficiency in pseudocontinuous arterial spin labeling. Magn Reson Med (2010) 1.91
Engineering hydrogels as extracellular matrix mimics. Nanomedicine (Lond) (2010) 1.86
Shear stress regulates forward and reverse planar cell polarity of vascular endothelium in vivo and in vitro. Circ Res (2006) 1.84
Care for the caregivers: a review of self-report instruments developed to measure the burden, needs, and quality of life of informal caregivers. J Pain Symptom Manage (2003) 1.84
Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol (2007) 1.84
Cancer screening among patients with advanced cancer. JAMA (2010) 1.82
Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol (2005) 1.81
Establishment of transcriptional competence in early and late S phase. Nature (2002) 1.81
An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg (2002) 1.80
Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis. Chest (2009) 1.80
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood (2010) 1.77
Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol (2005) 1.76
Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care (2009) 1.76
AtPID: Arabidopsis thaliana protein interactome database--an integrative platform for plant systems biology. Nucleic Acids Res (2007) 1.76
Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol (2004) 1.75
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol (2008) 1.75
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol (2007) 1.74
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol (2011) 1.74
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol (2003) 1.73
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol (2008) 1.73
Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology (2005) 1.69
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv (2010) 1.65
Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control (2006) 1.64
Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol (2002) 1.63
Alterations in cerebral metabolic rate and blood supply across the adult lifespan. Cereb Cortex (2010) 1.63
Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care (2009) 1.62